A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant Ascites

Sponsor
Anhui Provincial Hospital
Study ID
NCT06415500
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Gynecologic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • NK042 — DRUG
    NK042 intraperitoneal infusion on Days 0,7 and 14.

Study Details

The purpose of this study is to assess the safety and efficacy of NK042 for treatment of malignant ascites.

Key Dates

First listed
May 16, 2024
Start date
May 6, 2024
Status verified
May 2024
Primary completion
Dec 6, 2025
Completion
Dec 6, 2026

Study Design

Enrollment
9 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: NK042

Primary Outcome Measure

Maximum Tolerated Dose (MTD) and Dose-limiting Toxicity (DLT) [ Time Frame: 28 Days ]

Central Contacts

Related Studies